Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 among infants with sickle cell disease
Autore:
OBrien, KL; Swift, AJ; Winkelstein, JA; Santosham, M; Stover, B; Luddy, R; Gootenberg, JE; Nold, JT; Eskenazi, A; Snader, SJ; Lederman, HM;
Indirizzi:
Johns Hopkins Univ Hosp, Sch Hyg & Publ Hlth, Baltimore, MD 21205 USA Johns Hopkins Univ Hosp Baltimore MD USA 21205 h, Baltimore, MD 21205 USA Johns Hopkins Univ Hosp, Sch Med, Dept Pediat, Baltimore, MD 21205 USA Johns Hopkins Univ Hosp Baltimore MD USA 21205 t, Baltimore, MD 21205 USA Sinai Hosp, Baltimore, MD 21215 USA Sinai Hosp Baltimore MD USA 21215Sinai Hosp, Baltimore, MD 21215 USA Georgetown Univ, Sch Med, Washington, DC USA Georgetown Univ Washington DC USA town Univ, Sch Med, Washington, DC USA Pediat Ctr Annapolis, Annapolis, MD USA Pediat Ctr Annapolis Annapolis MDUSA t Ctr Annapolis, Annapolis, MD USA Univ Maryland, Sch Med, Dept Pediat, Baltimore, MD 21201 USA Univ Maryland Baltimore MD USA 21201 Dept Pediat, Baltimore, MD 21201 USA
Titolo Testata:
PEDIATRICS
fascicolo: 5, volume: 106, anno: 2000,
parte:, 1
pagine: 965 - 972
SICI:
0031-4005(200011)106:5<965:SAIOHP>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
ALTERNATIVE COMPLEMENT PATHWAY; STREPTOCOCCUS-PNEUMONIAE; CHILDREN; ANEMIA; POLYSACCHARIDE; IMMUNIZATION; OPSONIZATION; PROPHYLAXIS; PENICILLIN; EXPERIENCE;
Keywords:
pneumococcus; sickle cell disease; conjugate vaccine; Prevnar;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
27
Recensione:
Indirizzi per estratti:
Indirizzo: O'Brien, KL Johns Hopkins Univ Hosp, Sch Hyg & Publ Hlth, 621 N WashingtonSt, Baltimore, MD 21205 USA Johns Hopkins Univ Hosp 621 N Washington St Baltimore MD USA 21205
Citazione:
K.L. O'Brien et al., "Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 among infants with sickle cell disease", PEDIATRICS, 106(5), 2000, pp. 965-972

Abstract

Objectives. To determine the immunogenicity and safety of heptavalent pneumococcal polysaccharide vaccine (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) conjugated to CRM197 (7-valent conjugate pneumococcal vaccine [7VPnC]) among infants with sickle cell disease (SCD) and a comparison group of infants without SCD (non-SCD). Design. Two cohorts of infants were enrolled and received open-label dosesof 7VPnC vaccine; infants enrolled before 2 months of age received 7VPnC vaccine at 2, 4, and 6 months of age followed by 23-valent pneumococcal polysaccharide vaccine (PS-23) at 24 months of age for those infants with SCD (schedule A), and infants enrolled between 2 and 12 months of age received 7VPnC at 12 months of age followed by PS-23 at 24 months of age for infants with SCD (schedule B). Safety data were collected for 3 days after each dose of vaccine. Antibody concentrations were measured to each of the 7VPnC serotypes by enzyme-linked immunosorbent assay before each vaccine dose and 1month after the last 7VPnC dose and the PS-23 vaccine dose. Results. Forty-five infants (34 SCD and 11 non-SCD) were vaccinated according to schedule A and 16 infants (13 SCD and 3 non-SCD) according to schedule B. The 7VPnC vaccine was highly immunogenic for all serotypes among: infants with and without SCD who received 3 doses of vaccine according to schedule A: depending on serotype, 89% to 100% achieved antibody concentrationsabove .15 mug/mL and 56% to 100% achieved antibody concentrations above 1.0 mug/mL. Among infants immunized according to schedule B, a single dose of7VPnC vaccine resulted in antibody concentrations above .15 mug/mL in 53% to 92% by serotype and above 1.0 mug/mL in 31% to 71% by serotype. A singledose of PS-23 resulted in dramatic increases in the antibody concentrations to all serotypes regardless of 1- or 9-dose priming. There was no difference in the reactogenicity of the 7VPnC vaccine between those with and without SCD. There were no serious reactions to the 7VPnC or PS-23 vaccines, even among those with high antibody concentrations before immunization. Conclusions. Infants with SCD respond to 7VPnC vaccine with antibody concentrations that are at least as high as infants without SCD. Infants immunized with 7VPnC vaccine at 2, 4, and 6 months of age developed antibody concentrations in the same range as those achieved among infants without SCD enrolled in a large trial that demonstrated vaccine efficacy against invasive disease. Significant rises were seen in antibody concentrations to all 7VPnC serotypes after the PS-23 booster in children receiving: schedule A or B.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/10/20 alle ore 16:10:07